Columbia University Medical Center


Jeremy Veenstra-Vanderweele, MD

Jeremy Veenstra-Vanderweele, MD
  • Department of Psychiatry
    Division of Child and Adolescent Psychiatry
  • Professor of Psychiatry

Director, Division of Child and Adolescent PsychiatryCo-Director, NIMH T32 Postdoctoral Fellowship for Translational Research in Child Psychiatric DisordersCo-Director, Whitaker Scholar Program in Developmental Neuropsychiatry

The Veenstra-VanderWeele lab is dedicated to helping children with autism spectrum disorder (ASD) or obsessive compulsive disorder (OCD) and their families. We are approaching this goal using a variety of techniques, from animal models to research in adults with ASD. The majority of our efforts go toward developing and studying mouse models to understand the relationship between ASD or OCD risk factors and the resulting changes in brain and behavior. We are also working to translate laboratory research findings into novel treatments for children and adults with autism spectrum disorders or related genetic syndromes.


Jeremy Veenstra-VanderWeele, MD, is the Mortimer D. Sackler, MD, Associate Professor of Psychiatry at Columbia University Medical Center; Director of the Division of Child & Adolescent Psychiatry at NewYork-Presbyterian/Morgan Stanley Children’s Hospital, New York State Psychiatric Institute (NYSPI), and Columbia University; and Co-Director of both the NIMH T32 Postdoctoral Fellowship for Translational Research in Child Psychiatric Disorders and the Whitaker Scholar Program in Developmental Neuropsychiatry at NYSPI/Columbia University Medical Center. Dr. Veenstra-VanderWeele is a child and adolescent psychiatrist who uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism spectrum disorder and pediatric obsessive-compulsive disorder. He trained in human molecular genetics in the laboratory of Edwin H. Cook at the University of Chicago. Following his child and adolescent psychiatry fellowship, he expanded his research experience with a postdoctoral research fellowship in molecular neuroscience with Randy Blakely and Jim Sutcliffe at Vanderbilt University. Prior to joining the Department of Psychiatry at Columbia in 2014, Dr. Veenstra-VanderWeele was director of the Division of Child and Adolescent Psychiatry at Vanderbilt University, where he was also an associate professor and medical director for the Treatment and Research Institute for Autism Spectrum Disorder.

Dr. Veenstra-VanderWeele’s laboratory at Columbia University and NYSPI focuses on the serotonin and glutamate systems in genetic mouse models with abnormal social or repetitive/compulsive-like behavior. His clinical/translational research program at the NewYork-Presbyterian Hospital Center for Autism and the Developing Brain studies potential treatments for autism spectrum disorder and related genetic syndromes. His long-term goal is to be able to develop novel approaches in the molecular laboratory that can then be tested in children. Dr. Veenstra-VanderWeele’s work has been recognized with multiple awards, including the 2017 Blanche Ittelson Award for Research in Child and Adolescent Psychiatry from the American Psychiatric Association. He is dedicated to helping train and develop the next generation of child psychiatrists and scientists who can generate improved understanding of childhood neuropsychiatric disorders and deliver new treatments to the clinic.

Education & Training

  • MD, Pritzker School of Medicine at the University of Chicago
  • Residency: University of Chicago Hospitals
  • Fellowship: University of Chicago Hospitals
  • Primary Lab Locations

    CUMC/Herbert Pardes Building of the New York State Psychiatric Institute

    1051 Riverside Drive
    New York, NY 10032

    (646) 774-5251

    Lab Locations

    Center for the Developing Brain (CADB)

    21 Bloomingdale Road
    White Plains, NY 10605

    (914) 997-5848

    Contact Information

    Research Interests

    Autism Spectrum Disorder (ASD)
    Obsessive Compulsive Disorder (OCD)

    Lab Members


    • Veenstra-VanderWeele J, Muller CL, Iwamoto H, Sauer JE, Owens WA, Cohen J, Shah C, Mannangatti P, Jessen T, Thompson BJ, Carneiro AMD, Crawley JN, Sanders-Bush E, McMahon DG, Ramamoorthy S, Daws LC, Sutcliffe JS, Blakely RD: Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proceedings of the National Academy of Sciences USA 2012;109: 5469-5474
    • Hammock EA#, Veenstra-VanderWeele J#, Yan Z, Kerr TM, Morris M, Anderson GM, Carter CS, Cook EH, Jacob S (# Equal contribution): Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems. Journal of the American Academy of Child and Adolescent Psychiatry 2012;51: 712-721
    • Muller CL, Anacker AMJ, Veenstra-VanderWeele J (2016). The serotonin system in autism spectrum disorder: from biomarker to animal models. Neuroscience 321: 24-41.
    • Anagnostou E, Aman MG, Handen BL, Sanders KB, Shui A, Hollway JA, Brian J, Arnold LE, Capano L, Hellings JA, Butter E, Mankad D, Tumuluru R, Kettel J, Newsom C, Peleg N, Odrobina D, McAuliffe-Bellin S, Zakroysky P, Marler S, Wagner A, Wong T, Macklin EA, Veenstra-VanderWeele J (In Press). A randomized, placebo controlled trial of metformin for the treatment of overweight induced by antipsychotic medication in young people with ASD. JAMA Psychiatry.
    • Muller CL, Anacker AMJ, Rogers TD, Keller E, Goeden N, Forsberg KG, Kerr T, Shah CS, Wallace MT, Anderson GM, Stanwood GD, Bonnin A, Blakely RD, Veenstra-VanderWeele J (In Press). Maternal genotype of an autism risk variant impacts placental and forebrain serotonin system. Neuropsychopharmacology.